Lantern Pharma | 8-K: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.39, beating the estimate of USD -0.47.

EBIT: As of FY2025 Q3, the actual value is USD -4.451 M.

Cash, cash equivalents, and marketable securities: $12.4 million as of September 30, 2025, compared to $24.0 million as of December 31, 2024. The company expects this to fund operating expenses and capital expenditure requirements into approximately Q3 2026.

R&D expenses: $2.4 million for the quarter ended September 30, 2025, compared to $3.7 million for the quarter ended September 30, 2024. The decrease was primarily due to reductions in research studies and materials, consulting expenses, and payroll and compensation expenses, partially offset by increased licensing expenses.

G&A expenses: $1.9 million for the quarter ended September 30, 2025, compared to $1.5 million for the quarter ended September 30, 2024. The increase was mainly due to higher business development and investor relations expenditures, other professional fees, and patent costs.

Net loss: $4.2 million (or $0.39 per share) for the quarter ended September 30, 2025, compared to $4.5 million (or $0.42 per share) for the quarter ended September 30, 2024.

Shares of common stock outstanding: Approximately 11.0 million as of September 30, 2025. Options to purchase approximately 1.2 million shares of common stock at a weighted average exercise price of $5.74 per share were outstanding. No warrants were outstanding as of September 30, 2025.
ATM Sales Agreement: Entered in July 2025 with ThinkEquity LLC, allowing the company to offer and sell up to $15,530,000 of its common stock. During the quarter ended September 30, 2025, 212,444 shares were sold for gross proceeds of $989,061. An additional 144,204 shares were sold between October 1, 2025, and the date of the press release for gross proceeds of $634,333.

Near-Term Milestones (Q4 2025): November 20, 2025, KOL hosted scientific webinar on LP-184 Phase 1a results; December 2025, LP-300 further patient follow-up and clinical data; Q4 2025, continued commercial developments for AI platform modules.
Early 2026 Catalysts: Q1 2026, planned Pediatric CNS cancer trial initiation; Q1 2026, planned initiation of LP-184 Phase 1b/2 trials in TNBC and NSCLC; H1 2026, investigator-led bladder cancer trial initiation in Denmark; 2026, additional HARMONIC™ trial data readouts and potential partnership announcements; scale-up of AI platform commercial efforts; preparation for potential capital formation activities to support clinical advancement.